Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...

Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Mizuho analyst Graig Suvannavejh said, though the overall survival rate was encouraging, it was much lower than the six-month rate of 94% or the nine-month rate of 86%, "reflecting a greater ...

Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, manageable safety, and key ...

The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News ...

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated ...

The PAAG regimen significantly improved PFS and response rates in metastatic pancreatic cancer compared to chemotherapy alone ...

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

Middlesex County Freeholder Director Ronald G. Rios (center) cuts the ribbon to begin last year's Pancreatic Cancer Walk at Roosevelt Park in Edison. The event is held each year to raise awareness ...

SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system ...